We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$10.2B
AUM Growth
+$793M
Cap. Flow
+$230M
Cap. Flow %
2.25%
Top 10 Hldgs %
30.33%
Holding
229
New
13
Increased
77
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.7M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$44M
3
IQV icon
IQVIA
IQV
+$40.5M
4
MGNX icon
MacroGenics
MGNX
+$39.5M
5
SAGE
Sage Therapeutics
SAGE
+$39.1M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$222M
2
MRNA icon
Moderna
MRNA
+$47.8M
3
CI icon
Cigna
CI
+$47.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$40.5M
5
DVA icon
DaVita
DVA
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.41%
2 Industrials 0.94%
3 Technology 0.31%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GKOS icon
76
Glaukos
GKOS
$9.21B
$42M 0.41%
495,432
+6,090
+1% +$500K
HCAT icon
77
Health Catalyst
HCAT
$166M
$41.8M 0.41%
753,621
+11,766
+2% +$627K
TFX icon
78
Teleflex
TFX
$5.96B
$40.2M 0.39%
100,161
-21,200
-17% -$8.69M
MRSN
79
DELISTED
Mersana Therapeutics
MRSN
$39.9M 0.39%
117,640
+3,640
+3% +$1.38M
ADPT icon
80
Adaptive Biotechnologies
ADPT
$3.67B
$39.3M 0.38%
+962,352
New +$37.4M
OPCH icon
81
Option Care Health
OPCH
$3.41B
$39.2M 0.38%
1,790,192
+281,872
+19% +$5.43M
HZNP
82
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$39.1M 0.38%
417,700
+9,200
+2% +$847K
PHR icon
83
Phreesia
PHR
$662M
$38.2M 0.37%
622,542
+9,529
+2% +$496K
QTRX icon
84
Quanterix
QTRX
$182M
$37.4M 0.37%
637,815
-59,617
-9% -$3.46M
NEO icon
85
NeoGenomics
NEO
$1.9B
$37M 0.36%
818,313
+30,360
+4% +$1.35M
ABBV icon
86
AbbVie
ABBV
$450B
$36.5M 0.36%
324,200
-59,900
-16% -$6.75M
ILMN icon
87
Illumina
ILMN
$28.2B
$35.6M 0.35%
77,439
+14,815
+24% +$5.97M
EXAS
88
DELISTED
Exact Sciences
EXAS
$34.3M 0.33%
275,673
+57,533
+26% +$6.87M
HCM icon
89
HUTCHMED
HCM
$1.86B
$34M 0.33%
864,760
-110,728
-11% -$3.2M
AMGN icon
90
Amgen
AMGN
$198B
$31.6M 0.31%
129,580
-46,860
-27% -$11.5M
MASI
91
DELISTED
Masimo
MASI
$31M 0.3%
127,713
+1,517
+1% +$346K
NVRO
92
DELISTED
NEVRO CORP.
NVRO
$30.4M 0.3%
183,201
+2,188
+1% +$342K
ATRC icon
93
AtriCure
ATRC
$1.77B
$29.7M 0.29%
374,418
-123,294
-25% -$8.96M
COO icon
94
Cooper Companies
COO
$14B
$29.4M 0.29%
297,064
+19,596
+7% +$1.92M
ONC
95
BeOne Medicines Ltd
ONC
$32.4B
$28.9M 0.28%
84,300
+24,600
+41% +$8.15M
ONEM
96
DELISTED
1Life Healthcare
ONEM
$27.6M 0.27%
836,190
+13,055
+2% +$493K
AMWL icon
97
American Well
AMWL
$221M
$26.9M 0.26%
107,088
+13,666
+15% +$3.94M
VCRA
98
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$26M 0.25%
652,832
+160,725
+33% +$5.87M
NEUE
99
DELISTED
NeueHealth
NEUE
$25.7M 0.25%
+18,750
New +$25.7M
KZR
100
DELISTED
Kezar Life Sciences
KZR
$24.6M 0.24%
453,315
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bellevue Group held 229 positions worth $10.2B, up 8.4% from $9.45B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q2 2021 filing shows 13 new, 77 increased, 41 reduced and 15 closed positions. Its largest new stake was Adaptive Biotechnologies: 962,352 shares worth $39.3M. The largest sale was Alexion Pharmaceuticals, an estimated $222M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2021 buy was Adaptive Biotechnologies: 962,352 shares worth $39.3M.
  • Bellevue Group added most to Vertex Pharmaceuticals in Q2 2021, an estimated $74.7M increase.
  • Bellevue Group's biggest Q2 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $222M.
  • Bellevue Group fully exited DaVita in Q2 2021, selling an estimated $39.6M.
  • Bellevue Group's ten largest holdings make up 30% of its $10.2B portfolio in Q2 2021.
  • Bellevue Group opened 13 new positions and closed 15 in Q2 2021.
  • Bellevue Group's portfolio value rose 8.4% quarter-over-quarter to $10.2B.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.